Edition:
India

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

78.35CHF
6:57pm IST
Change (% chg)

CHF0.60 (+0.77%)
Prev Close
CHF77.75
Open
CHF78.00
Day's High
CHF79.05
Day's Low
CHF77.05
Volume
31,371
Avg. Vol
56,671
52-wk High
CHF95.35
52-wk Low
CHF70.10

Select another date:

Wed, Jan 3 2018

BRIEF-Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​

* ‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​

BRIEF-Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA

* BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Extends Existing License Agreement With Pfizer For Cresemba

* BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC

BRIEF-Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​

* ‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea: Marc Engelhardt named new Chief Medical Officer

* BASILEA'S CHIEF MEDICAL OFFICER PROF. ACHIM KAUFHOLD TO RETIRE AND DR. MARC ENGELHARDT NAMED AS SUCCESSOR

BRIEF-Basilea Pharmaceutica says ‍sales of antifungal cresemba in US exceeded threshold

* BASILEA PHARMACEUTICA - ‍SALES OF ANTIFUNGAL CRESEMBA IN US TRIGGER 1ST SALES MILESTONE PAYMENT FROM ASTELLAS PHARMA OF CHF 5 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea announces license with Shenzhen China Resources Gosun Pharmaceutical Co

* BASILEA ANNOUNCES LICENSE AGREEMENT FOR ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE) WITH SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

BRIEF-Basilea reports significant progress on partnering and development programs

* Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs Source text for Eikon: Further company coverage:

BRIEF-Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​

* ‍56 PERCENT INCREASE IN TOTAL H1 REVENUE, AMOUNTING TO CHF 46.2 MILLION​

Select another date: